Clinical study of remazolam combined with propofol for painless endoscopy in obese patients

Comparison of remiazolam combined with propofol and propofol alone for painless endoscopy in obese patients

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065022

Enrollment

Unknown

Registered

2022-10-26

Start date

2022-11-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:propofol united Remazolam

Control group:propofol

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Patients to undergo gastrointestinal endoscopy; 2. 28 <= BMI <= 32; 3. Age 18-65; 4. ASA classification I-III; 5. Markovian classification I-II; 6. Normal in spirit and able to communicate normally.

Exclusion criteria

Exclusion criteria: 1. Refusing to participate in this study; 2. Have serious liver, kidney, heart, brain and lung diseases, ASA III or above; 3. Patients with severe airway difficulties were evaluated, and the Markovian classification was >= III; 4. Stop bang score >= 6, or patients who need ventilator assisted sleep; 5. Patients with mental illness; 6. Patients who abuse narcotic analgesics and sedatives; 7. Unable to communicate normally and cooperate with patients.

Design outcomes

Primary

Measure	Time frame
frequency of hypoxia;	—

Secondary

Measure	Time frame
propofol consumption per minute;Wake up time;Incidence rate of dizziness, nausea and vomiting;	—

Countries

China

Contacts

Public ContactXuan Zhao

Shanghai Tenth People's Hospital

zhaoxuan1026@hotmail.com13052082279

Outcome results